Oncotype DX® reimbursed

Test Oncotype DX® is reimbursed from the major health insurer in Czech Republic VZP from the 1st December 2013 for patients with Early Breast Cancer hormonal positive, HER2 negative with Grade 2 and one of risk factors (high Ki67). This Insurer covers 60% of the total population (6 Milion covered lives) in Czech Republic. Reimbursement is restricted to 13 Comprehensive Cancer Centers, list of these centers you can find at website www.linkos.cz.